Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 12, 2016, Pages 1293-1299

  Ungar, B ^a   Mazor, Y ^b   Weisshof, R ^b   Yanai, H ^a   Ron, Y ^a   Goren, I ^a   Waizbard, A ^a   Yavzori, M ^a   Fudim, E ^a   Picard, O ^a   Loebstein, R ^a   Kopylov, U ^a   Dotan, I ^a   Chowers, Y ^b   Eliakim, R ^a   Ben Horin, S ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLON RESECTION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CLEARANCE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS; ACUTE DISEASE; BLOOD; CLINICAL TRIAL; COLITIS, ULCERATIVE; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; COLITIS, ULCERATIVE; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84963959717     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13631     Document Type: Article

References (30)

1. Dinesen LC, Walsh AJ, Protic MN, et al,. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4: 431-7.
2. D'Haens G, Lemmens L, Geboes K, et al,. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
3. Roberts SE, Williams JG, Yeates D, et al,. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 2007; 335: 1033.
4. Seagrove AC, Alam MF, Alrubaiy L, et al,. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: trial design and protocol (CONSTRUCT). BMJ Open 2014; 4: e005091.
5. Laharie D, Bourreille A, Branche J, et al,. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
6. Ordas I, Feagan BG, Sandborn WJ,. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 1079-87, quiz e85-6
7. Ungar B CY, Yavzori M, Picard O, et al,. The temporal evolution of anti-drug antibodies in inflammatory bowel disease patients treated with infliximab. Gut 2014; 63: 1258-64.
8. Seow CH, Newman A, Irwin SP, et al,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
9. Sandborn WJ, Rutgeerts P, Feagan BG, et al,. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60; quiz 1520.
10. Brandse JF, van den Brink GR, Wildenberg ME, et al,. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 2015; 149: 350-5.
11. Higgins PD, Schwartz M, Mapili J, et al,. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-8.
12. Harvey RF, Bradshaw JM,. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
13. Vermeire S, Schreiber S, Sandborn WJ, et al,. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-63.
14. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
15. Ben-Horin S, Kopylov U, Chowers Y,. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014; 13: 24-30.
16. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
17. Kopylov U, Mazor Y, Yavzori M, et al,. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012; 18: 1628-33.
18. Siegel CA, Melmed GY,. Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol 2009; 2: 245-51.
19. Yarur AJ, Jain A, Sussman DA, et al,. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2016; 65: 249-55.
20. Gibson DJ, Heetun ZS, Redmond CE, et al,. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-5 e1.
21. David Kevans SM, Iacono A, Silverberg MS, Greenberg GR,. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology 2012; 42: S384-5.
22. Papamichael K, Van Stappen T, Vande Casteele N, et al,. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2016; 14: 543-9.
23. Fasanmade AA, Adedokun OJ, Olson A, et al,. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48: 297-308.
24. Monterubbianesi R, Aratari A, Armuzzi A, et al,. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis 2014; 8: 852-8.
25. Lindgren SC, Flood LM, Kilander AF, et al,. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.
26. Hoekman DR, Brandse JF, de Meij TG, et al,. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 1110-7.
27. Roblin X, Marotte H, Rinaudo M, et al,. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80-4 e2.
28. Cornillie F, Hanauer SB, Diamond RH, et al,. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-7.
29. Dotan I, Ron Y, Yanai H, et al,. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 2014; 20: 2247-59.
30. Ben-Horin S, Waterman M, Kopylov U, et al,. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444-7.